Migraine attacks halved by antibody therapies

Written by Lauren Pulling, Editor

Novartis (Basel, Switzerland) have announced positive results from the 6-month Phase III STRIVE study evaluating erenumab for the prevention of episodic migraine, reporting that 50% of patients taking the drug had their number of migraine days cut by at least half. In addition, Teva Pharmaceuticals (Jerusalem, Israel) have published data from the Phase III HALO study for another monoclonal antibody, fremanezumab, for chronic migraine, showing that 41% of treated patients halved their number of migraine days. The STRIVE study enrolled 955 patients who were randomized to receive with placebo or subcutaneous erenumab 70mg or 140mg once a month for 6...

To view this content, please register now for access

It's completely free